|
The
oleic acid component of the troyamine injection is responsible
for the inflammatory response, and may also activate coagulation
by release of tissue factor and activation of Hageman factor.
Indication:
Troyamine
injection is indicated for the treatment of patients with
esophageal varices that have recently bled, to prevent rebleeding.
Troyamine is not indicated for the treatment of patients
with esophageal varices that have not bled. There is no evidence
that treatment of this population decreases the likelihood
of bleeding.
|
|
 |
|
Dosage
& Administration:
Local
Troyamine injection sclerotherapy of esophageal varices should
be performed by physicians who are familiar with an acceptable
technique. The usual intravenous dose is 1.5 to 5 ml. per
varix. The maximum dose per treatment session should not exceed
20 ml. Submucosal injections are not recommended as
they are reportedly more likely to result in ulceration at
the site of injection. To obliterate the varix, injections
may be made at the time of the acute bleeding episode and
then after one week, six weeks, three months, and six months
as indicated.
Note: Parenteral drug products should be inspected
visually for particulate matter and discoloration before administration
whenever solution and container permit.
Availability:
5
% solution 5ml ampoule
|
